Get the full xynova company profile
Access contacts, investors, buying signals & more
Xynova has raised $29.6M in Series A funding. The company describes itself as a trail of informational breadcrumbs left behind while walking - an unusual framing that offers little about what it actually builds or sells.
No investors were disclosed, and the company did not say what the capital will be used for.
Humanoid Investments: 2026 YTD : $9.75B+ Here's the breakdown: January 2026 Skild AI – $1.
4B (Series C) Zhejiang Humanoid Robot Innovation Center – ≈$64M PHYBOT – >$14M (Seed) Futuring Robot – ≈$29M (Seed) X Square Robot – ≈$143M (Series A) February 2026 LimX Dynamics – $200M (Series B) PNDbotics – >$29M X Square Robot – >$29M AI² Robotics – >$143M (Series B) Unbounded Dynamics – >$29M (Seed) Linkerbot – ≈$215M (Series B) Apptronik – $520M (Series A-X extension) Galaxea AI – ≈$144M (
Kinoxis Therapeutics Pty Ltd
Kinoxis Therapeutics Pty Ltd is a private, Australian-based, clinical-stage biotechnology company developing first-in-class therapeutics targeting ALOX15, a key regulator of neuroinflammation and neural excitability in the brain. By modulating disease-relevant biological pathways, Kinoxis is advancing mechanism-based precision therapies to address significant unmet medical needs in neuropsychiatric and central nervous system disorders. Kinoxis’ lead clinical candidate, KNX100, is a first-in-class, short-acting small-molecule inhibitor of ALOX15 being developed for the treatment of acute agitation and aggression associated with dementia and other neuropsychiatric conditions. The compound has demonstrated robust activity across multiple preclinical models and was shown to be safe and well tolerated in a completed Phase 1 clinical study conducted under a U.S. Investigational New Drug (IND) application. KNX100 is currently being evaluated in the CARES-X Phase 2 clinical trial, a multi-site study in Australia assessing its safety, tolerability, and efficacy in patients with agitation associated with dementia. In parallel, Kinoxis is advancing KNX101, a second-generation, long-acting ALOX15 inhibitor designed to address acute and chronic pain and chronic agitation through sustained modulation of neuroinflammatory signalling pathways. These programs form part of Kinoxis’ broader strategy to deliver novel, non-opioid and non-sedating therapies for patients living with complex neurological and psychiatric conditions.
$6.8M Seed
2 days ago
Largest funding rounds in Education on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  IconiQ | Unknown | $5.8B | 2y ago |
| 2 |  BYJU'S India | Unknown | $5.1B | 2y ago |
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Five Ages Germany | Series a | $29.5M | today |
| 2 |  ActivTrak United States | Series a | $20.0M | today |
lubdub.ai
Never miss a beat with accessible and smart heart diagnostics. Our technology combines precision hardware with advanced analytics. Ultra-light and wireless wearable + advanced analytics and medical insights.
$6.0M Seed
2 days ago
| 3 |  COLUMBIA Peru | Grant | $5.0B | 1y ago |
| 4 |  Cloud Counselage Pvt. Ltd. India | Unknown | $5.0B | 1y ago |
| 5 |  FutureScholé South Korea | Series a | $4.0B | 2y ago |
| 3 |
 Zonos United States |
| Series a |
| $69.0M |
| 1d ago |
| 4 |  Split Pay United States | Series a | $25.0M | 1d ago |
| 5 |  ViferaXS Germany | Series a | $13.7M | 1d ago |
Trusted by 200+ sales teams
See who invested in xynova and reach their contacts directly.
Start free trialunbounded-dynamics
Recently received
phybot
Recently received
Pluntum
Recently received
